Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn

Miqdad, AM; Abdelbasit, Omer B.; Shaheed, MM; Seidahmed, MZ; Abomelha, AM; Arcala, OP

doi:10.1080/14767050400009873

Cited by 17 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IVIG group infants also required decreased duration of phototherapy and had shorter hospital stays than the control group. Another RCT compared treatment with IVIG or placebo in newborns with AB0 hemolytic disease and found that the IVIG-treated newborns had reduced need for PE[ 60]. …”

Section: Indications With Substantial Evidence For Use As a First-linmentioning

confidence: 99%

Intravenous Immunoglobulin: Striving for Appropriate Use

Kumar¹,

Teuber²,

Gershwin³

2006

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Intravenous immunoglobulin (IVIG) is the mainstay therapy in human immune deficiency states characterized by qualitative and quantitative reductions in B cells. In addition, however, there is widespread use of IVIG in a number of other areas, including neuroimmunologic, infectious, dermatologic, hematologic, autoimmune, inflammatory and idiopathic disorders. In many of these cases, there are little objective data to support the use. Methods: We performed a review of more than 400 publications in PubMed using the key words ‘intravenous immunoglobulin’ and excluded publications that focused on immune deficiency, for which the indication for IVIG is already clear. Results: For a number of off-label indications, there is significant evidence of efficacy and IVIG has become the standard of care for many clinical syndromes other than immune deficiency. In some conditions, however, the data have not been well controlled or randomized and are often limited to case reports that are difficult to interpret. Although the critical shortage of IVIG of the last decade is no longer an issue, IVIG is expensive and not without risk. The use of IVIG should be based not only on clinical data, but also, and especially, on the biological rationale for its use. Conclusions: The appropriate use of IVIG is an important issue that is difficult to resolve, and will continue to challenge clinicians based on expense and potentially limited supply, including the intrinsic limitations of donor plasma. The establishment of national and international voluntary registries to report use of IVIG in disorders for which evidence is lacking would be a first step toward facilitating randomized, controlled clinical trials.

show abstract

Section: Indications With Substantial Evidence For Use As a First-linmentioning

confidence: 99%